Heejin Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Heejin Kwon has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Siobhan Kierans
Weill Cornell Medical College, New York, USA
7 shared publications - Hanyu Jiang
Department of Radiology West China Hospital, Sichuan University Chengdu China
7 shared publications - Ijin Joo
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak‑ro, Jongno‑gu, Seoul 03080, Korea
7 shared publications Jinhan Cho
Department of Radiology Dong‐A University Hospital Busan Republic of Korea
7 shared publications- Joanna Podgórska
Second Department of Radiology, Medical University of Warsaw, Warsaw, Poland
7 shared publications - Sang Hyun Choi
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
7 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Simplifying CT / MRI LI ‐ RADS v2018 Maintains Diagnostic Performance: An Individual Participant Data Meta‐Analysis
Background: The Liver Imaging Reporting and Data System (LI‐RADS) diagnostic algorithm assesses hepatocellular carcinoma (HCC) probability of liver observations in high‐risk individuals, but complexity may limit its adoption. Purpose: To evaluate whether LI‐RADS v2018 can be simplified without impairing diagnostic performance by removing threshold growth (TG) and reducing size cut‐offs. Study Type: Retrospective meta‐analysis. Population: Eight thousand five hundred eighty‐two patients (mean age: 59 ± 11 years; 6610 male) at risk for HCC with CT/MRI (986 CT, 6554 MRI, and 1042 CT/MRI). Field Strength/Sequence: Field strength: 1.5T and 3.0T; sequences varied by institution per LI‐RADS technical requirements. Assessment: LI‐RADS v2018 using major features only was compared with seven simplifications removing TG and/or applying single size cut‐offs (≥ 10, ≥ 15, and ≥ 20 mm) in individual participant data (IPD) of 64 studies (29 institutions, 11 countries) from the LI‐RADS Living Systematic Review and IPD Meta‐analysis Project. Risk of bias was assessed with QUADAS‐2. Statistical Tests: Summary receiver operating characteristic curves estimated area under the curve (AUC) across LR‐3 to LR‐5; LR‐5 sensitivity, specificity, and positive predictive value (PPV) were estimated using a one‐step bivariate mixed‐effects model. Differences were assessed by cluster bootstrap. p < 0.05 indicated significance, uncorrected for multiple comparisons. Results: Nine thousand four hundred six observations were included. Excluding TG with a 10‐mm cut‐off showed AUC similar to LI‐RADS v2018 (0.80 vs. 0.81, p = 0.44) and significantly higher LR‐5 sensitivity (73.8% vs. 71.8%) with similar specificity (72.5% vs. 73.7%, p = 0.13) and PPV (97.8% vs. 97.8%, p = 0.73). Removing TG with 15‐mm and 20‐mm cut‐offs had significantly lower AUC than v2018 (−0.03 [95% CI: −0.041, −0.019]; −0.043 [−0.054, −0.032], respectively) and sensitivity (−13.2% [95% CI: −14.5%, −12.0%]; −30.1% [−31.7%, −28.5%], respectively). Of the 64 studies, 17 had low‐risk of bias, and 56 had low applicability concerns. Conclusion: Simplifying LI‐RADS v2018 by removing TG and using a 10‐mm size cut‐off preserved diagnostic table AUC while improving LR‐5 sensitivity without loss of specificity or PPV. Protocol Registration: Open Science Framework ( https://osf.io/cjwgp ). Evidence Level: 3. Technical Efficiency: Stage 2.
- 2 November 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Open AccessSimplifying CT / MRI LI ‐ RADS v2018 Maintains Diagnostic Performance: An Individual Participant Data Meta‐Analysis
Background: The Liver Imaging Reporting and Data System (LI‐RADS) diagnostic algorithm assesses hepatocellular carcinoma (HCC) probability of liver observations in high‐risk individuals, but complexity may limit its adoption. Purpose: To evaluate whether LI‐RADS v2018 can be simplified without impairing diagnostic performance by removing threshold growth (TG) and reducing size cut‐offs. Study Type: Retrospective meta‐analysis. Population: Eight thousand five hundred eighty‐two patients (mean age: 59 ± 11 years; 6610 male) at risk for HCC with CT/MRI (986 CT, 6554 MRI, and 1042 CT/MRI). Field Strength/Sequence: Field strength: 1.5T and 3.0T; sequences varied by institution per LI‐RADS technical requirements. Assessment: LI‐RADS v2018 using major features only was compared with seven simplifications removing TG and/or applying single size cut‐offs (≥ 10, ≥ 15, and ≥ 20 mm) in individual participant data (IPD) of 64 studies (29 institutions, 11 countries) from the LI‐RADS Living Systematic Review and IPD Meta‐analysis Project. Risk of bias was assessed with QUADAS‐2. Statistical Tests: Summary receiver operating characteristic curves estimated area under the curve (AUC) across LR‐3 to LR‐5; LR‐5 sensitivity, specificity, and positive predictive value (PPV) were estimated using a one‐step bivariate mixed‐effects model. Differences were assessed by cluster bootstrap. p < 0.05 indicated significance, uncorrected for multiple comparisons. Results: Nine thousand four hundred six observations were included. Excluding TG with a 10‐mm cut‐off showed AUC similar to LI‐RADS v2018 (0.80 vs. 0.81, p = 0.44) and significantly higher LR‐5 sensitivity (73.8% vs. 71.8%) with similar specificity (72.5% vs. 73.7%, p = 0.13) and PPV (97.8% vs. 97.8%, p = 0.73). Removing TG with 15‐mm and 20‐mm cut‐offs had significantly lower AUC than v2018 (−0.03 [95% CI: −0.041, −0.019]; −0.043 [−0.054, −0.032], respectively) and sensitivity (−13.2% [95% CI: −14.5%, −12.0%]; −30.1% [−31.7%, −28.5%], respectively). Of the 64 studies, 17 had low‐risk of bias, and 56 had low applicability concerns. Conclusion: Simplifying LI‐RADS v2018 by removing TG and using a 10‐mm size cut‐off preserved diagnostic table AUC while improving LR‐5 sensitivity without loss of specificity or PPV. Protocol Registration: Open Science Framework ( https://osf.io/cjwgp ). Evidence Level: 3. Technical Efficiency: Stage 2.
- Open Access
- 1 January 2026
- Published by XMLink in Investigative Magnetic Resonance Imaging
- Vol. 30 (3) , 204-212
Deep Learning–Based SmartSpeed Precise Diffusion-Weighted Imaging for Hepatocellular Carcinoma: Comparison With Conventional Diffusion-Weighted Imaging
Jang J, et al. Investig Magn Reson Imaging. 2026 Sep;30(3):204-212. https://doi.org/10.13104/imri.2026.0025
- 1 January 2026
- Published by XMLink in Investigative Magnetic Resonance Imaging
- Vol. 30 (3) , 204-212
Open AccessDeep Learning–Based SmartSpeed Precise Diffusion-Weighted Imaging for Hepatocellular Carcinoma: Comparison With Conventional Diffusion-Weighted Imaging
Jang J, et al. Investig Magn Reson Imaging. 2026 Sep;30(3):204-212. https://doi.org/10.13104/imri.2026.0025
- Open Access
- 1 January 2026
- Published by XMLink in Journal of the Korean Society of Radiology
- Vol. 87 (3) , 586-591
Primary Gastric Leiomyosarcoma Presenting as an Endoscopic Diagnostic Pitfall: A Case Report
구본재, et al. J Korean Soc Radiol. 2026 May;87(3):586-591. https://doi.org/10.3348/jksr.2025.0098
- 1 January 2026
- Published by XMLink in Journal of the Korean Society of Radiology
- Vol. 87 (3) , 586-591
Open AccessPrimary Gastric Leiomyosarcoma Presenting as an Endoscopic Diagnostic Pitfall: A Case Report
구본재, et al. J Korean Soc Radiol. 2026 May;87(3):586-591. https://doi.org/10.3348/jksr.2025.0098
- 1 June 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (3) , e243450
Diagnostic Performance of CT/MRI LI-RADS Version 2018 Major Feature Combinations: Individual Participant Data Meta-Analysis
This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.
- 1 June 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (3) , e243450
Diagnostic Performance of CT/MRI LI-RADS Version 2018 Major Feature Combinations: Individual Participant Data Meta-Analysis
This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.
- Open Access
- 6 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (49) , e40769
Predicting prognosis prior to the combination of atezolizumab and bevacizumab on unresectable HCC: Analysis and comparison of tumor heterogeneity at CT and Gd-EOB-DTPA hepatobiliary MR imaging
Since 2007, the combination of atezolizumab and bevacizumab, comprising an immune checkpoint inhibitor and a molecularly targeted agent, has become the first-line treatment for advanced hepatocellular carcinoma (HCC). Predicting prognosis prior to systemic chemotherapy remains a critical concern. This study included 84 advanced HCC patients who underwent enhanced computed tomography (CT) and Gd-EOB-DTPA magnetic resonance imaging (MRI) before the systemic therapy were included. In CT, the 2 radiologists measured mean CT Hounsfield unit (CTHU) value by drawing region of interest at the largest diameter of the tumor on arterial phage. The HU values were categorized into 5 groups: ≤ 0, 0 < HU ≤ 50, 50 < HU ≤ 100, 100 < HU ≤ 150, and HU > 150. The percentage of the entire tumor in each category was calculated. On MRI, hepatobiliary phase imaging features and relative enhancement ratio (RER) were also evaluated by 2 radiologists. Prognostic factors associated with progression-free survival were identified using statistical analysis. RER on HBP MRI correlated with prognosis in systemic chemotherapy. Conversely, other image features on HBP MRI and CT histogram provided consistent treatment effect.
- 6 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (49) , e40769
Open AccessPredicting prognosis prior to the combination of atezolizumab and bevacizumab on unresectable HCC: Analysis and comparison of tumor heterogeneity at CT and Gd-EOB-DTPA hepatobiliary MR imaging
Since 2007, the combination of atezolizumab and bevacizumab, comprising an immune checkpoint inhibitor and a molecularly targeted agent, has become the first-line treatment for advanced hepatocellular carcinoma (HCC). Predicting prognosis prior to systemic chemotherapy remains a critical concern. This study included 84 advanced HCC patients who underwent enhanced computed tomography (CT) and Gd-EOB-DTPA magnetic resonance imaging (MRI) before the systemic therapy were included. In CT, the 2 radiologists measured mean CT Hounsfield unit (CTHU) value by drawing region of interest at the largest diameter of the tumor on arterial phage. The HU values were categorized into 5 groups: ≤ 0, 0 < HU ≤ 50, 50 < HU ≤ 100, 100 < HU ≤ 150, and HU > 150. The percentage of the entire tumor in each category was calculated. On MRI, hepatobiliary phase imaging features and relative enhancement ratio (RER) were also evaluated by 2 radiologists. Prognostic factors associated with progression-free survival were identified using statistical analysis. RER on HBP MRI correlated with prognosis in systemic chemotherapy. Conversely, other image features on HBP MRI and CT histogram provided consistent treatment effect.
- 27 September 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (4) , 1533-1546
Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis
Background The Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations. Purpose To evaluate whether the presence of a concurrent LR-5 observation is associated with a difference in the probability that LR-3 or LR-4 observations represent hepatocellular carcinoma (HCC) through an individual participant data (IPD) meta-analysis. Methods Multiple databases were searched from 1/2014 to 2/2023 for studies evaluating the diagnostic accuracy of CT/MRI for HCC using LI-RADS v2014/2017/2018. The search strategy, study selection, and data collection process can be found at https://osf.io/rpg8x. Using a generalized linear mixed model (GLMM), IPD were pooled across studies and modeled simultaneously with a one-stage meta-analysis approach to estimate positive predictive value (PPV) of LR-3 and LR-4 observations without and with concurrent LR-5 for the diagnosis of HCC. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Results Twenty-nine studies comprising 2591 observations in 1456 patients (mean age 59 years, 1083 [74%] male) were included. 587/1960 (29.9%) LR-3 observations in 1009 patients had concurrent LR-5. The PPV for LR-3 observations with concurrent LR-5 was not significantly different from the PPV without LR-5 (45.4% vs 37.1%, p = 0.63). 264/631 (41.8%) LR-4 observations in 447 patients had concurrent LR-5. The PPV for LR-4 observations with concurrent LR-5 was not significantly different from LR-4 observations without concurrent LR-5 (88.6% vs 69.5%, p = 0.08). A sensitivity analysis for low-risk of bias studies (n = 9) did not differ from the primary analysis. Conclusion The presence of concurrent LR-5 was not significantly associated with differences in PPV for HCC in LR-3 or LR-4 observations, supporting the current LI-RADS paradigm, wherein the presence of synchronous LR-5 may not alter the categorization of LR-3 and LR-4 observations.
- 27 September 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (4) , 1533-1546
Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis
Background The Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations. Purpose To evaluate whether the presence of a concurrent LR-5 observation is associated with a difference in the probability that LR-3 or LR-4 observations represent hepatocellular carcinoma (HCC) through an individual participant data (IPD) meta-analysis. Methods Multiple databases were searched from 1/2014 to 2/2023 for studies evaluating the diagnostic accuracy of CT/MRI for HCC using LI-RADS v2014/2017/2018. The search strategy, study selection, and data collection process can be found at https://osf.io/rpg8x. Using a generalized linear mixed model (GLMM), IPD were pooled across studies and modeled simultaneously with a one-stage meta-analysis approach to estimate positive predictive value (PPV) of LR-3 and LR-4 observations without and with concurrent LR-5 for the diagnosis of HCC. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Results Twenty-nine studies comprising 2591 observations in 1456 patients (mean age 59 years, 1083 [74%] male) were included. 587/1960 (29.9%) LR-3 observations in 1009 patients had concurrent LR-5. The PPV for LR-3 observations with concurrent LR-5 was not significantly different from the PPV without LR-5 (45.4% vs 37.1%, p = 0.63). 264/631 (41.8%) LR-4 observations in 447 patients had concurrent LR-5. The PPV for LR-4 observations with concurrent LR-5 was not significantly different from LR-4 observations without concurrent LR-5 (88.6% vs 69.5%, p = 0.08). A sensitivity analysis for low-risk of bias studies (n = 9) did not differ from the primary analysis. Conclusion The presence of concurrent LR-5 was not significantly associated with differences in PPV for HCC in LR-3 or LR-4 observations, supporting the current LI-RADS paradigm, wherein the presence of synchronous LR-5 may not alter the categorization of LR-3 and LR-4 observations.
- Open Access
- 22 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1083
Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis
Background: Non-alcoholic fatty liver disease (NAFLD) encompasses a heterogeneous spectrum ranging from simple steatosis to fibrosis and cirrhosis. Fibrosis, associated with long-term overall mortality and liver-related events, requires evaluation. Traditionally, liver biopsy has been the gold standard for diagnosing fibrosis. However, its invasive nature, potential complications, and sampling variability limit widespread use. Consequently, various non-invasive tests have been developed as alternatives for diagnosing fibrosis in NAFLD patients. Aim: This study aimed to compare the accuracy of non-invasive tests (NITs) and evaluate the diagnostic accuracy of acoustic radiation force impulse (ARFI), one of the point shear wave techniques, compared to conventional methods, assessing its effective role in diagnosis. Methods: This is a retrospective study; a total of 136 patients diagnosed with fatty liver disease through ultrasonography were enrolled. The anthropometric data of the patients were collected on the day of admission and blood tests, measurements of ARFI, and a point shear test were conducted using abdominal ultrasound; a biopsy was performed the following day. In addition, we calculated the aspartate aminotransferase-to-platelet ratio index (APRI) index based on four factors (FIB-4) and the NAFLD fibrosis score (NFS). Subsequently, we assessed the diagnostic accuracy of NITs within various subgroups based on the extent of obesity, steatosis, or NAFLD activity score. Results: ARFI has been shown to have the highest diagnostic value among various NITs, with AUROC values of 0.832, 0.794, 0.767, and 0.696 for ARFI, APRI, FIB-4, and NFS, respectively. In the morbidly obese subgroup, the AUROC values of ARFI, APRI, FIB-4, and NFS were 0.805, 0.769, 0.736, and 0.674. In the group with severe steatosis or non-alcoholic steatohepatitis (NASH), the AUROC values were 0.679, 0.596, 0.661, and 0.612, respectively, for severe steatosis and 0.789, 0.696, 0.751, and 0.691, respectively, for NASH. Conclusions: In conclusion, ARFI is not affected by various factors and maintains diagnostic accuracy compared to serum NITs. Therefore, we can recommend ARFI as a valuable diagnostic test to screen for advanced fibrosis in patients with NAFLD.
- 22 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1083
Open AccessAssessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis
Background: Non-alcoholic fatty liver disease (NAFLD) encompasses a heterogeneous spectrum ranging from simple steatosis to fibrosis and cirrhosis. Fibrosis, associated with long-term overall mortality and liver-related events, requires evaluation. Traditionally, liver biopsy has been the gold standard for diagnosing fibrosis. However, its invasive nature, potential complications, and sampling variability limit widespread use. Consequently, various non-invasive tests have been developed as alternatives for diagnosing fibrosis in NAFLD patients. Aim: This study aimed to compare the accuracy of non-invasive tests (NITs) and evaluate the diagnostic accuracy of acoustic radiation force impulse (ARFI), one of the point shear wave techniques, compared to conventional methods, assessing its effective role in diagnosis. Methods: This is a retrospective study; a total of 136 patients diagnosed with fatty liver disease through ultrasonography were enrolled. The anthropometric data of the patients were collected on the day of admission and blood tests, measurements of ARFI, and a point shear test were conducted using abdominal ultrasound; a biopsy was performed the following day. In addition, we calculated the aspartate aminotransferase-to-platelet ratio index (APRI) index based on four factors (FIB-4) and the NAFLD fibrosis score (NFS). Subsequently, we assessed the diagnostic accuracy of NITs within various subgroups based on the extent of obesity, steatosis, or NAFLD activity score. Results: ARFI has been shown to have the highest diagnostic value among various NITs, with AUROC values of 0.832, 0.794, 0.767, and 0.696 for ARFI, APRI, FIB-4, and NFS, respectively. In the morbidly obese subgroup, the AUROC values of ARFI, APRI, FIB-4, and NFS were 0.805, 0.769, 0.736, and 0.674. In the group with severe steatosis or non-alcoholic steatohepatitis (NASH), the AUROC values were 0.679, 0.596, 0.661, and 0.612, respectively, for severe steatosis and 0.789, 0.696, 0.751, and 0.691, respectively, for NASH. Conclusions: In conclusion, ARFI is not affected by various factors and maintains diagnostic accuracy compared to serum NITs. Therefore, we can recommend ARFI as a valuable diagnostic test to screen for advanced fibrosis in patients with NAFLD.
- 1 February 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 310 (2) , e231501
LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis
Background The independent contribution of each Liver Imaging Reporting and Data System (LI-RADS) CT or MRI ancillary feature (AF) has not been established. Purpose To evaluate the association of LI-RADS AFs with hepatocellular carcinoma (HCC) and malignancy while adjusting for LI-RADS major features through an individual participant data (IPD) meta-analysis. Materials and Methods Medline, Embase, Cochrane Central Register of Controlled Trials, and Scopus were searched from January 2014 to January 2022 for studies evaluating the diagnostic accuracy of CT and MRI for HCC using LI-RADS version 2014, 2017, or 2018. Using a one-step approach, IPD across studies were pooled. Adjusted odds ratios (ORs) and 95% CIs were derived from multivariable logistic regression models of each AF combined with major features except threshold growth (excluded because of infrequent reporting). Liver observation clustering was addressed at the study and participant levels through random intercepts. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2. Results Twenty studies comprising 3091 observations (2456 adult participants; mean age, 59 years ± 11 [SD]; 1849 [75.3%] men) were included. In total, 89% (eight of nine) of AFs favoring malignancy were associated with malignancy and/or HCC, 80% (four of five) of AFs favoring HCC were associated with HCC, and 57% (four of seven) of AFs favoring benignity were negatively associated with HCC and/or malignancy. Nonenhancing capsule (OR = 3.50 [95% CI: 1.53, 8.01]) had the strongest association with HCC. Diffusion restriction (OR = 14.45 [95% CI: 9.82, 21.27]) and mild-moderate T2 hyperintensity (OR = 10.18 [95% CI: 7.17, 14.44]) had the strongest association with malignancy. The strongest negative associations with HCC were parallels blood pool enhancement (OR = 0.07 [95% CI: 0.01, 0.49]) and marked T2 hyperintensity (OR = 0.18 [95% CI: 0.07, 0.45]). Seventeen studies (85%) had a high risk of bias. Conclusion Most LI-RADS AFs were independently associated with HCC, malignancy, or benignity as intended when adjusting for major features. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Crivellaro in this issue.
- 1 February 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 310 (2) , e231501
LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis
Background The independent contribution of each Liver Imaging Reporting and Data System (LI-RADS) CT or MRI ancillary feature (AF) has not been established. Purpose To evaluate the association of LI-RADS AFs with hepatocellular carcinoma (HCC) and malignancy while adjusting for LI-RADS major features through an individual participant data (IPD) meta-analysis. Materials and Methods Medline, Embase, Cochrane Central Register of Controlled Trials, and Scopus were searched from January 2014 to January 2022 for studies evaluating the diagnostic accuracy of CT and MRI for HCC using LI-RADS version 2014, 2017, or 2018. Using a one-step approach, IPD across studies were pooled. Adjusted odds ratios (ORs) and 95% CIs were derived from multivariable logistic regression models of each AF combined with major features except threshold growth (excluded because of infrequent reporting). Liver observation clustering was addressed at the study and participant levels through random intercepts. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2. Results Twenty studies comprising 3091 observations (2456 adult participants; mean age, 59 years ± 11 [SD]; 1849 [75.3%] men) were included. In total, 89% (eight of nine) of AFs favoring malignancy were associated with malignancy and/or HCC, 80% (four of five) of AFs favoring HCC were associated with HCC, and 57% (four of seven) of AFs favoring benignity were negatively associated with HCC and/or malignancy. Nonenhancing capsule (OR = 3.50 [95% CI: 1.53, 8.01]) had the strongest association with HCC. Diffusion restriction (OR = 14.45 [95% CI: 9.82, 21.27]) and mild-moderate T2 hyperintensity (OR = 10.18 [95% CI: 7.17, 14.44]) had the strongest association with malignancy. The strongest negative associations with HCC were parallels blood pool enhancement (OR = 0.07 [95% CI: 0.01, 0.49]) and marked T2 hyperintensity (OR = 0.18 [95% CI: 0.07, 0.45]). Seventeen studies (85%) had a high risk of bias. Conclusion Most LI-RADS AFs were independently associated with HCC, malignancy, or benignity as intended when adjusting for major features. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Crivellaro in this issue.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e231656
Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis
Background A simplification of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), revised LI-RADS (rLI-RADS), has been proposed for imaging-based diagnosis of hepatocellular carcinoma (HCC). Single-site data suggest that rLI-RADS category 5 (rLR-5) improves sensitivity while maintaining positive predictive value (PPV) of the LI-RADS v2018 category 5 (LR-5), which indicates definite HCC. Purpose To compare the diagnostic performance of LI-RADS v2018 and rLI-RADS in a multicenter data set of patients at risk for HCC by performing an individual patient data meta-analysis. Materials and Methods Multiple databases were searched for studies published from January 2014 to January 2022 that evaluated the diagnostic performance of any version of LI-RADS at CT or MRI for diagnosing HCC. An individual patient data meta-analysis method was applied to observations from the identified studies. Quality Assessment of Diagnostic Accuracy Studies version 2 was applied to determine study risk of bias. Observations were categorized according to major features and either LI-RADS v2018 or rLI-RADS assignments. Diagnostic accuracies of category 5 for each system were calculated using generalized linear mixed models and compared using the likelihood ratio test for sensitivity and the Wald test for PPV. Results Twenty-four studies, including 3840 patients and 4727 observations, were analyzed. The median observation size was 19 mm (IQR, 11-30 mm). rLR-5 showed higher sensitivity compared with LR-5 (70.6% [95% CI: 60.7, 78.9] vs 61.3% [95% CI: 45.9, 74.7]; P < .001), with similar PPV (90.7% vs 92.3%; P = .55). In studies with low risk of bias (n = 4; 1031 observations), rLR-5 also achieved a higher sensitivity than LR-5 (72.3% [95% CI: 63.9, 80.1] vs 66.9% [95% CI: 58.2, 74.5]; P = .02), with similar PPV (83.1% vs 88.7%; P = .47). Conclusion rLR-5 achieved a higher sensitivity for identifying HCC than LR-5 while maintaining a comparable PPV at 90% or more, matching the results presented in the original rLI-RADS study. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Sirlin and Chernyak in this issue.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e231656
Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis
Background A simplification of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), revised LI-RADS (rLI-RADS), has been proposed for imaging-based diagnosis of hepatocellular carcinoma (HCC). Single-site data suggest that rLI-RADS category 5 (rLR-5) improves sensitivity while maintaining positive predictive value (PPV) of the LI-RADS v2018 category 5 (LR-5), which indicates definite HCC. Purpose To compare the diagnostic performance of LI-RADS v2018 and rLI-RADS in a multicenter data set of patients at risk for HCC by performing an individual patient data meta-analysis. Materials and Methods Multiple databases were searched for studies published from January 2014 to January 2022 that evaluated the diagnostic performance of any version of LI-RADS at CT or MRI for diagnosing HCC. An individual patient data meta-analysis method was applied to observations from the identified studies. Quality Assessment of Diagnostic Accuracy Studies version 2 was applied to determine study risk of bias. Observations were categorized according to major features and either LI-RADS v2018 or rLI-RADS assignments. Diagnostic accuracies of category 5 for each system were calculated using generalized linear mixed models and compared using the likelihood ratio test for sensitivity and the Wald test for PPV. Results Twenty-four studies, including 3840 patients and 4727 observations, were analyzed. The median observation size was 19 mm (IQR, 11-30 mm). rLR-5 showed higher sensitivity compared with LR-5 (70.6% [95% CI: 60.7, 78.9] vs 61.3% [95% CI: 45.9, 74.7]; P < .001), with similar PPV (90.7% vs 92.3%; P = .55). In studies with low risk of bias (n = 4; 1031 observations), rLR-5 also achieved a higher sensitivity than LR-5 (72.3% [95% CI: 63.9, 80.1] vs 66.9% [95% CI: 58.2, 74.5]; P = .02), with similar PPV (83.1% vs 88.7%; P = .47). Conclusion rLR-5 achieved a higher sensitivity for identifying HCC than LR-5 while maintaining a comparable PPV at 90% or more, matching the results presented in the original rLI-RADS study. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Sirlin and Chernyak in this issue.
- Open Access
- 1 December 2023
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 60 (3) , 1082-1091
Comparative Performance of 2018 LI‐RADS versus Modified LIRADS (mLI‐RADS): An Individual Participant Data Meta‐Analysis
Background: LI‐RADS version 2018 (v2018) is used for non‐invasive diagnosis of hepatocellular carcinoma (HCC). A recently proposed modification (known as mLI‐RADS) demonstrated improved sensitivity while maintaining specificity and positive predictive value (PPV) of LI‐RADS category 5 (definite HCC) for HCC. However, mLI‐RADS requires multicenter validation.Purpose: To evaluate the performance of v2018 and mLI‐RADS for liver lesions in a large, heterogeneous, multi‐national cohort of patients at risk for HCC.Study Type: Systematic review and meta‐analysis using individual participant data (IPD) [Study Protocol: https://osf.io/duys4].Population: 2223 observations from 1817 patients (includes all LI‐RADS categories; females = 448, males = 1361, not reported = 8) at elevated risk for developing HCC (based on LI‐RADS population criteria) from 12 retrospective studies.Field Strength/Sequence: 1.5T and 3T; complete liver MRI with gadoxetate disodium, including axial T2w images and dynamic axial fat‐suppressed T1w images precontrast and in the arterial, portal venous, transitional, and hepatobiliary phases. Diffusion‐weighted imaging was used when available.Assessment: Liver observations were categorized using v2018 and mLI‐RADS. The diagnostic performance of each system's category 5 (LR‐5 and mLR‐5) for HCC were compared.Statistical Tests: The Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS‐2 was applied to determine risk of bias and applicability. Diagnostic performances were assessed using the likelihood ratio test for sensitivity and specificity and the Wald test for PPV. The significance level was P < 0.05.Results: 17% (2/12) of the studies were considered low risk of bias (244 liver observations; 164 patients). When compared to v2018, mLR‐5 demonstrated higher sensitivity (61.3% vs. 46.5%, P < 0.001), similar PPV (85.3% vs. 86.3%, P = 0.89), and similar specificity (85.8% vs. 90.8%, P = 0.16) for HCC.Data Conclusion: This study confirms mLR‐5 has higher sensitivity than LR‐5 for HCC identification, while maintaining similar PPV and specificity, validating the mLI‐RADS proposal in a heterogeneous, international cohort.Level of Evidence: 3Technical Efficacy: Stage 2
- 1 December 2023
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 60 (3) , 1082-1091
Open AccessComparative Performance of 2018 LI‐RADS versus Modified LIRADS (mLI‐RADS): An Individual Participant Data Meta‐Analysis
Background: LI‐RADS version 2018 (v2018) is used for non‐invasive diagnosis of hepatocellular carcinoma (HCC). A recently proposed modification (known as mLI‐RADS) demonstrated improved sensitivity while maintaining specificity and positive predictive value (PPV) of LI‐RADS category 5 (definite HCC) for HCC. However, mLI‐RADS requires multicenter validation.Purpose: To evaluate the performance of v2018 and mLI‐RADS for liver lesions in a large, heterogeneous, multi‐national cohort of patients at risk for HCC.Study Type: Systematic review and meta‐analysis using individual participant data (IPD) [Study Protocol: https://osf.io/duys4].Population: 2223 observations from 1817 patients (includes all LI‐RADS categories; females = 448, males = 1361, not reported = 8) at elevated risk for developing HCC (based on LI‐RADS population criteria) from 12 retrospective studies.Field Strength/Sequence: 1.5T and 3T; complete liver MRI with gadoxetate disodium, including axial T2w images and dynamic axial fat‐suppressed T1w images precontrast and in the arterial, portal venous, transitional, and hepatobiliary phases. Diffusion‐weighted imaging was used when available.Assessment: Liver observations were categorized using v2018 and mLI‐RADS. The diagnostic performance of each system's category 5 (LR‐5 and mLR‐5) for HCC were compared.Statistical Tests: The Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS‐2 was applied to determine risk of bias and applicability. Diagnostic performances were assessed using the likelihood ratio test for sensitivity and specificity and the Wald test for PPV. The significance level was P < 0.05.Results: 17% (2/12) of the studies were considered low risk of bias (244 liver observations; 164 patients). When compared to v2018, mLR‐5 demonstrated higher sensitivity (61.3% vs. 46.5%, P < 0.001), similar PPV (85.3% vs. 86.3%, P = 0.89), and similar specificity (85.8% vs. 90.8%, P = 0.16) for HCC.Data Conclusion: This study confirms mLR‐5 has higher sensitivity than LR‐5 for HCC identification, while maintaining similar PPV and specificity, validating the mLI‐RADS proposal in a heterogeneous, international cohort.Level of Evidence: 3Technical Efficacy: Stage 2